CIBC Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$51.8M Sell
104,292
-2,601
-2% -$1.15M 0.11% 132
2026
Q1
$47.7M Sell
106,893
-748
-0.7% -$349K 0.12% 135
2025
Q4
$48.8M Buy
107,641
+26,636
+33% +$11.5M 0.12% 134
2025
Q3
$31.7M Buy
81,005
+19
+0% +$7.94K 0.09% 147
2025
Q2
$36.1M Sell
80,986
-4,393
-5% -$2.02M 0.11% 129
2025
Q1
$41.4M Buy
85,379
+888
+1% +$414K 0.14% 114
2024
Q4
$34M Buy
84,491
+4,389
+5% +$2.03M 0.11% 129
2024
Q3
$37.3M Buy
80,102
+4,432
+6% +$2.13M 0.12% 120
2024
Q2
$35.5M Sell
75,670
-674
-0.9% -$293K 0.13% 119
2024
Q1
$31.9M Buy
76,344
+4,236
+6% +$1.79M 0.11% 129
2023
Q4
$29.3M Buy
72,108
+7
+0% +$2.59K 0.11% 132
2023
Q3
$25.1M Buy
72,101
+7,169
+11% +$2.51M 0.1% 137
2023
Q2
$22.9M Sell
64,932
-376
-0.6% -$127K 0.09% 153
2023
Q1
$20.6M Buy
65,308
+847
+1% +$254K 0.08% 158
2022
Q4
$18.6M Sell
64,461
-1,577
-2% -$481K 0.08% 160
2022
Q3
$19.1M Buy
66,038
+3,115
+5% +$896K 0.08% 151
2022
Q2
$17.7M Sell
62,923
-4,664
-7% -$1.25M 0.07% 152
2022
Q1
$17.6M Sell
67,587
-55
-0.1% -$13.1K 0.06% 171
2021
Q4
$14.9M Buy
67,642
+6,305
+10% +$1.23M 0.05% 185
2021
Q3
$11.1M Buy
61,337
+4,109
+7% +$802K 0.04% 213
2021
Q2
$11.5M Buy
57,228
+2,690
+5% +$563K 0.05% 213
2021
Q1
$11.7M Buy
54,538
+6,965
+15% +$1.53M 0.05% 200
2020
Q4
$11.2M Buy
47,573
+3,021
+7% +$693K 0.05% 201
2020
Q3
$12.1M Buy
44,552
+6,032
+16% +$1.66M 0.06% 172
2020
Q2
$11.2M Buy
38,520
+1,144
+3% +$310K 0.07% 166
2020
Q1
$8.89M Buy
37,376
+664
+2% +$152K 0.06% 170
2019
Q4
$8.04M Buy
36,712
+1,421
+4% +$288K 0.05% 184
2019
Q3
$5.98M Sell
35,291
-183
-0.5% -$32.4K 0.04% 219
2019
Q2
$6.5M Buy
35,474
+987
+3% +$173K 0.04% 202
2019
Q1
$6.34M Sell
34,487
-22
-0.1% -$4.06K 0.04% 202
2018
Q4
$5.72M Buy
34,509
+601
+2% +$104K 0.04% 182
2018
Q3
$6.54M Buy
33,908
+627
+2% +$112K 0.04% 182
2018
Q2
$5.66M Buy
33,281
+1,986
+6% +$308K 0.04% 202
2018
Q1
$5.1M Sell
31,295
-247
-0.8% -$40.3K 0.03% 213
2017
Q4
$4.73M Sell
31,542
-310
-1% -$45.9K 0.03% 233
2017
Q3
$4.84M Buy
31,852
+641
+2% +$96.5K 0.03% 223
2017
Q2
$4.02M Buy
31,211
+977
+3% +$118K 0.03% 249
2017
Q1
$3.31M Buy
30,234
+531
+2% +$46.7K 0.02% 283
2016
Q4
$2.19M Buy
29,703
+415
+1% +$33.8K 0.02% 369
2016
Q3
$2.55M Sell
29,288
-1,924
-6% -$182K 0.02% 330
2016
Q2
$2.69M Buy
31,212
+511
+2% +$44.2K 0.02% 313
2016
Q1
$2.44M Buy
30,701
+709
+2% +$64.1K 0.02% 328
2015
Q4
$3.77M Buy
29,992
+13
+0% +$1.57K 0.03% 224
2015
Q3
$3.12M Buy
29,979
+397
+1% +$51K 0.03% 258
2015
Q2
$3.65M Buy
29,582
+1,341
+5% +$169K 0.03% 258
2015
Q1
$3.33M Buy
28,241
+2,054
+8% +$246K 0.02% 271
2014
Q4
$3.11M Sell
26,187
-6,798
-21% -$766K 0.02% 265
2014
Q3
$3.71M Sell
32,985
-122
-0.4% -$11.6K 0.02% 258
2014
Q2
$3.13M Sell
33,107
-1,022
-3% -$71.7K 0.02% 315
2014
Q1
$2.41M Buy
34,129
+4,954
+17% +$392K 0.01% 369
2013
Q4
$2.17M Buy
29,175
+709
+2% +$49.4K 0.01% 372
2013
Q3
$2.16M Buy
28,466
+17,889
+169% +$1.42M 0.01% 352
2013
Q2
$847K Buy
+10,577
New +$779K 0.01% 557

Other funds holding VRTX

CIBC Asset Management's VRTX Position: Q2 2026 in Review

CIBC Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q2 2026, selling an estimated $1.15M and leaving 104,292 shares worth $51.8M. The position accounts for 0.11% of the portfolio, ranked #132.

CIBC Asset Management first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • CIBC Asset Management held 104,292 shares of Vertex Pharmaceuticals worth $51.8M as of Q2 2026.
  • CIBC Asset Management sold 2,601 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.15M.
  • Vertex Pharmaceuticals made up 0.11% of CIBC Asset Management's portfolio in Q2 2026, its #132 holding.
  • CIBC Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.